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Abstract
Background:Hypertension is one of the commonmedical conditions observed among patients aged 50 years and elder living with
HIV (EPLWH) and to date no systematic review has estimated its global prevalence.
Purpose: To conduct a systematic review to estimate the global prevalence of hypertension among EPLWH.
Data Sources: PubMed/MEDLINE, Embase, the Cochrane Library, and Global Health databases for relevant publications up till
May 25, 2018.
StudySelection:Observational studies (cohort or cross-sectional studies) that estimated the prevalence of hypertension among
EPLWH.
Data Extraction: Required data were extracted independently by three reviewers and the main outcome was hypertension
prevalence among EPLWH.
Data Synthesis: The 24 (n=29,987) eligible studies included were conducted in North America, Europe, Africa, and Asia. A low
level bias threat to the estimated hypertension prevalence rates was observed. The global prevalence of hypertension among EPLWH
was estimated at 42.0% (95% CI 29.6%–55.4%), I2=100%. The subgroup analysis showed that North America has the highest
prevalence of hypertension 50.2% (95% CI 29.2% –71.2%) followed by Europe 37.8% (95% CI 30.7%–45.7%) sub-Saharan Africa
31.9% (95% CI 18.5% –49.2%) and Asia 31.0% (95% CI 26.1%–36.3%). We found the mean age of the participants explaining a
considerable part of variation in hypertension prevalence.
Conclusion: This study demonstrated that two out of ﬁve EPLWH are hypertensive. North America appears to have the highest
prevalence of hypertension followed by Europe, sub-Saharan Africa (SSA) and Asia respectively. Findings from this study can be
utilized to integrate hypertension management to HIV management package. (Registration number: CRD42018103069)
Abbreviations: AIDS = acquired immunodeﬁciency syndrome, ART = advent of antiretroviral therapy , CI = conﬁdence interval,
DBP= diastolic blood pressure, EPLWH= elderly people living with HIV, HANA=HIV associated non-AIDS conditions , HIV= human
immunodeﬁciency virus, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PROSPERO =
International Prospective Register of Systematic Reviews, SBP = systolic blood pressure, SSA = Sub-Saharan Africa.
Keywords: elderly, HIV, hypertension prevalence
1. Introduction
Following the advent of antiretroviral therapy (ART), survival of
human immunodeﬁciency virus (HIV) infected patients has
improved dramatically due to decline in progression of the disease
to acquired immunodeﬁciency syndrome (AIDS) and HIV-related
deaths.[1–4]AsARTcoverage and retentionofHIV infectedpatients
on treatment increase, more HIV infected patients are attaining
geriatric age.[5]However, as life expectancyofHIV infectedpatients
is improving, studies have revealed important health implicationsof
HIV infection and ART among middle-aged and older adults.
Previous studies have shown thatHIV infection anduse ofARTcan
potentiate early onset of geriatric syndrome.[6,7]
In addition, it hasbeen reported that this newlyagingpopulation
of HIV infected patients are experiencing early onset of diseases
that are seen in older population of people who are not infected
with the virus. For example studies have revealed thatHIV infected
patients who are on ART were at higher risk of having HIV
associated non-AIDS conditions (HANA) such as hepatic, renal,
pulmonary, cancers, bone, neurological, metabolic and cardiovas-
cular diseases.[8–15] Of all these co-morbid conditions, cardiovas-
cular disease is the most important cause of deaths amongHANA
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conditions and its major underlying risk factor is hypertension.[16]
Cardiovascular disease occurs more and earlier in HIV-infected
patients thanHIV-uninfected patients because of their exposure to
HIV and ART. It is believed that HIV-induced immune activation
and/or ART-associated dyslipidemia facilitate early onset of
cardiovascular disease in HIV-infected patients.[17]
With the emergence of cardiovascular diseases, it is clinically
relevant to restructure HIV management to allow the integration
of cardiovascular diseases management into HIV management
package. It will be challenging to carry out this integration
without having adequate information on the prevalence of
hypertension among HIV-infected patients. Although few
systematic review studies have been conducted to estimate the
prevalence of hypertension among HIV-infected patients,[18–20]
none of these studies estimated the prevalence of hypertension
among elderly with HIV despite the strong synergy between HIV
and aging. Thus, it is the aim of this study to estimate the
prevalence of hypertension among elderly people living with HIV
(EPLWH) infection. This will serve as important information for
HIV program planning and implementation.
2. Methods
The study protocol for this systematic review was developed
based on the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines.[21] Detailed informa-
tion on the study rationale and methods were pre-speciﬁed in the
protocol registered in the International Prospective Register of
Systematic Reviews (PROSPERO) with an identiﬁcation number
CRD42018103069.
2.1. Data sources and searches
We followed standard guidelines for integrating existing
systematic reviews into new reviews.[22,23] Existing systematic
reviews on the prevalence of hypertension in people living with
HIV were used as a starting point to identify relevant studies and
searches were updated accordingly. We searched PubMed/
MEDLINE, Embase, the Cochrane Library, and Global Health
databases for relevant publications up till May 25, 2018, using
keywords related to HIV and hypertension. In addition, abstract
presentations in HIV/AIDS and infectious diseases conferences
were searched. Also, reference lists of identiﬁed publications
were checked for additional relevant articles. The search was
performed without restriction based on geographic location and
language. However, the update search was limited by year of
publication (January 2015 to May 25, 2018).
2.2. Eligibility criteria
We evaluated each identiﬁed study against the following
predeﬁned selection criteria:
2.3. Participants/population
Elderly population, aged 50 years and above living with HIV/
AIDS.
2.4. Exposure(s)
Treatment naïve or on any ART andwhether on antihypertensive
medications, statin or aspirin or not.
2.5. Comparator(s)
Not applicable.
2.6. Outcome
Essential hypertension (also called primary or idiopathic
hypertension), deﬁned as persistent systolic blood pressure
Table 1
Overall characteristics of included studies.
First author (year) Publication year Study design Study period Study location Sample size Mean age Percent male Diagnosis
Bryant et al (2015) 2015 Cross-sectional No report United States 79 59 68 MED
Greene et al (2014) 2014 Longitudinal 2008–2010 United States 89 63 94 MED
Hasse et al (2015) 2015 Longitudinal 2009–2011 Switzerland 3230 50 81 BP/MED
Metallidis et al (2013) 2013 Longitudinal 1998–2008 Greece 103 57.7 80.6 MR
Parikh et al (2015) 2015 Cross-sectional 2011 United States 150 52 88 MR
Patel et al (2013) 2013 Cross-sectional 2011 United States 454 51 71 MR
Tongma et al (2013) 2013 Cross-sectional No report United States 111 52 86 MR
Wu et al (2014) 2014 Cross-sectional 2013 Taiwan 310 58.8 84.5 BP
Balderson et al (2013) 2013 Cross-sectional No report United States 452 55.8 72 Self-report
Flexor et al (2013) 2013 Longitudinal 2004 France 149 65.4 77 BP/MED
Mothe et al (2009) 2009 Cross-sectional 2007 Spain 179 76 70 BP/MED
Onen et al (2010) 2010 Longitudinal 2006 United States 122 55.8 83 BP
Njelekela et al (2016) 2016 Cross-sectional No report Tanzania 3,317 50 No report BP
Van Zoest et at. (2017) 2107 Longitudinal 2010–2012 Netherlands 528 53 89 BP
Fontela et al (2018) 2018 Cross-sectional 2016 Spain 329 54 71 MR
Friedman et al (2016) 2016 Longitudinal 2006–2009 United States 24,735 71.1 58.3 MR
Van Zoest et at. (2016) 2016 Longitudinal 2010–2012 Netherlands 527 52.9 88.6 BP
Calcagno et al (2017) 2017 Cross-sectional 2015–2016 Italy 1,092 71.3 82.5 BP
Manne-Goehler et al (2017) 2017 Longitudinal 2014–2015 South Africa 1,035 55.4 55.6 BP
Kooij et al (2016) 2016 Longitudinal 2010–2012 Netherlands 556 52.7 71.5 BP
Domingues et al (2017) 2017 Longitudinal 2013–2014 Spain 42 57.5 92.9 BP
Hanna et al (2016) 2016 Longitudinal 2006–2014 United States 1,636 50 0 BP
Patel et al (2015) 2015 Cross-sectional 2008–2010 United Kingdom 299 59 94.6 Self-report
Miller et al (2015) 2015 Longitudinal 1984–2003 United States 453 52 100 MED
Methods of hypertension diagnosis: BP–average blood pressure >140/90mm Hg, MED—self-reported use of antihypertensive medication, MR—from medical records.
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(SBP) of ≥140 mmHg and/or had diastolic blood pressure (DBP)
≥90mm Hg regardless of age and sex or hypertension deducible
from the use of antihypertensive drugs or self-reported physician-
diagnosed cases. We excluded studies that included subjects
with pregnancy-induced hypertension, pre-eclampsia, malignant,
portal, pulmonary, renal, intracranial, or ocular hypertension.
2.7. Study selection
Three authors (GAK, OAU, and PD) independently assessed the
titles and abstracts of the publications found by our literature
search based on the eligibility criteria that we pre-speciﬁed in the
study protocol. All disagreements were resolved by evaluating the
whole article. We only included observational studies that
estimated the prevalence of hypertension among elderly people
with HIV.
2.8. Data extraction and quality assessment
Data were extracted from all the selected publications by three
authors independently (GAK, TA, and PD). Information on ﬁrst
author, study design, period of data collection, study location,
use of ART, sample size, average age of the participants,
prevalence of hypertension, and diagnosis of hypertension were
obtained. All discrepancies during data extraction were resolved
by consensus after discussion. We assessed the quality of the
selected studies using the critical appraisal tool for evaluating the
qualities of papers included in systematic reviews addressing
questions of prevalence.[24] The quality of articles included in
the analysis were assessed for the risk of bias in 7 domains:
representative sample, participants recruitment, adequate sample
size, appropriate description of participants and setting, data
completeness/nonresponse, unbiased outcome assessment, and
appropriate statistical analysis. We reported risk of bias in each
domain as low risk, high risk, or unclear.
2.9. Data synthesis and analysis
For the meta-analysis, we ﬁrst stabilise the raw prevalence of
estimate from each study using the logit transformation
proportion suitable for pooling and then pooled the prevalence
estimates using the DerSimonian–Laird random effects model.[25]
We performed leave-one-study-out sensitivity analysis to deter-
mine the stability of the results. This analysis evaluated the
inﬂuence of individual studies by estimating the pooled
hypertension prevalence in the absence of each study.[26] We
assessed the heterogeneity among studies by inspecting the forest
plots and using the chi-squared test for heterogeneity with a 10%
level of statistical signiﬁcance, and using the I2 statistic where
we interpreted a value of 50% as moderate heterogeneity.[27,28]
We assessed the possibility of publication bias by evaluating a
funnel plot for asymmetry. Because graphical evaluation can be
subjective, we also conducted Egger’s regression asymmetry
test[29] as formal statistical test for publication bias.
Furthermore, we explored the effect of study-level factors on
the overall pooled hypertension prevalence estimates using
subgroup and meta-regression analyses: publication year, study
design (cross-sectional or longitudinal study), study region
(North America, Europe, Africa, or Asia), sample size, mean
age, and percentage male. Univariable random-effects logistic
regression analysis was conducted to investigate the impact of
study-level factors (listed above) on the pooled hypertension
prevalence. Univariable random-effects logistic regression
analyses were used to investigate the bivariate relationship
between each study-level factor and prevalence of hypertension
estimates. Meta-analysis results were reported as combined
hypertension prevalence with 95% conﬁdence intervals (CIs),
while meta-regression results were reported as odds ratio with
95% CIs. All P-values were exact and P-values <.05 were
considered statistically signiﬁcant. Analyses were conducted
using Stata version 14 for Windows (Stata Corp, College Station,
Texas). This systematic review was reported according to the
PRISMA guideline.[21,30]
2.10. Role of the funding source
No funding was received to conduct this study
Figure 1. Risk of bias assessment of included studies.
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2.11. Ethical approval
We conducted a systematic review of published evidence; thus no
ethical clearance was required.
3. Results
3.1. Study characteristics
The PRISMA ﬂow diagram shows the results of the literature
search carried-out to identify and select eligible literature
published after the existing systematic reviews[18,19] that
were identiﬁed. In addition to the 12 eligible full-text articles
that were identiﬁed from the existing systematic reviews, the
results of the literature search yielded 560 citations. We identiﬁed
31 full-text articles for critical review after removing 529 articles
due to duplication of articles and failure to meet the eligibility
criteria. Of the 31 articles from the updated search that were
critically appraised, only 12 articles were included in the analysis;
indicating that a total of 24 articles were considered in the
analysis. Twenty-four studies, involving 29,987 elderly people
living with HIV met the inclusion criteria and were included
in this meta-analysis. Characteristics of included studies are
summarized in Table 1. The studies were published between 2009
and 2018. Most of the studies were from the United States of
Figure 2. Pooled prevalence of hypertension among patients aged 50 and older living with HIV.
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Figure 3. Leave-one-out sensitivity analyses.
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America (n=10, 41.7%) followed by the Netherlands (n=3,
12.5%) and Spain (n=3, 12.5%). The sample size ranged from
42 to 24,735 elderly people living with HIV (median=396). The
average age ranged from 50 to 76 years and percentage of male
ranged from 55.6% to 94.6%.
3.2. Risk of bias of included studies
The results of risk of bias assessment were presented in Figure 1.
About two-thirds of the articles included in the analysis have
sufﬁcient sample size and the data completeness and respondent
rate were adequate. However, only one-third of the articles could
be clearly judged to have a representative sample. In almost all the
articles, participants’ recruitment, description of the study
participants, and data analysis were adequate. Bias was
observed in the procedures for assessing outcome in two of
the articles while the degree of bias could not be ascertained in
three articles.
Figure 4. Pooled prevalence of hypertension among elderly people living with HIV by different subgroup.
Table 2
Factors associated with prevalence estimates identiﬁed by meta-
regression analysis.
Factor OR (95% CI) P-value
Explained
variation
(%)
Publication year 1.00 (0.88 to 1.15) .931 0.0
Design
Cross-sectional 1 (reference)
Longitudinal 1.06 (0.48 to 2.38) .873 0.0
Region 8.9
Asia 0.44 (0.11 to 1.76) .233
Europe 0.60 (0.33 to 1.07) .080
America 1 (reference)
Sub-Saharan Africa 0.46 (0.17 to 1.27) .127
Sample size 1.18 (0.98 to 1.43) .083 10.2
Mean age (per 10 year) 1.45 (1.01 to 2.09) .046 14.6
% male 1.00 (0.98 to 1.01) .479 0.0
Dakum et al. Medicine (2019) 98:15 Medicine
6
3.3. Prevalence of hypertension among elderly people
living with HIV
The prevalence rates of hypertension among elderly people living
with HIV and 95% CIs from individual studies with a pooled
estimate are shown in Figure 2. The pooled prevalence of
hypertension for all studies yielded an estimate of 42.0% (95%
CI 29.6% to 55.4%). The I2 statistics was 100%, indicating
statistically signiﬁcant heterogeneity among the studies. The
results of leave-one-study-out sensitivity analyses showed that no
study had undue inﬂuence on pooled hypertension prevalence
(Fig. 3). Figure 2 also show subgroup analysis by different
geographical regions. The prevalence of hypertension was
observed to be higher among studies conducted in North
America (50.2%, 95% CI 29.2%–71.2%, 10 studies, 28281
participants) compared with studies from Europe (37.8%, 95%
CI 30.5% to 45.7%, 11 studies, 7044 participants), sub-Saharan
Africa (SSA) (31.9%, 95% CI 18.5%–49.2%, 2 studies, 4352
participants) and Asia (31.0%, 95% CI 26.1%–36.3%, 1 study,
310 participants). However, this difference did not reach
statistically signiﬁcant level (p-value for interaction=0.312).
The pooled prevalence estimates from cross-sectional studies
(41.2%, 95% CI 30.8%–52.4%, 11 studies, 6782 participants)
and longitudinal studies (42.7%, 95% CI 26.0–61.1, 13 studies,
33205 participants) were similar (Fig. 4).
3.4. Factors modifying the prevalence of hypertension as
identiﬁed by meta-regression analysis
Factors associated with the prevalence estimates and proportion
of explained variability in the prevalence estimates as identiﬁed
by meta-regression analyses are shown in Table 2. In a series of
meta-regression analyses, only mean age was statistically
signiﬁcantly associated with the prevalence estimates; such that
for every 10 years increase in the mean age of the participants,
hypertension prevalence increased by 45% (OR=1.45, 95% CI
1.01–2.09) (Table 2). In addition, Figure 5 shows the relationship
between the mean age of the participants and hypertension
prevalence without ignoring the size of each study population.
Moreover, Figure 5 indicates that hypertension prevalence has a
direct relationship with mean age of the participants.
4. Discussion
To the best of our knowledge, this is the ﬁrst systematic review
that estimated the global prevalence of hypertension mainly in
EPLWH aged 50 years and older. The underlying factors
responsible for the observed differences inHIV prevalence among
the study populations were examined. We observed that about
42% of EPLWH aged≥50 years were hypertensive. This estimate
is in agreement with the observation made by Xu and
colleagues[19]; they found that the prevalence of hypertension
among EPLWH aged ≥50 years was 40.3%. This indicates that
out of 4.2 million EPLWH worldwide, about 2 million of them
are hypertensive.[31]
There was variation in hypertension prevalence among the
study populations. North America appear to have the highest
prevalence of hypertension among EPLWH aged ≥50 years,
followed by Europe, SSA, and Asia but the observed variation
was not statistically signiﬁcant. Among the factors considered in
the meta-regression analysis to explain the observed heterogene-
ity in hypertension prevalence, only the mean age of the
participants in each study was found to explain a considerable
part of variation in prevalence of hypertension among EPLWH
aged ≥50 years. This could be explained by the established
relationship between age and occurrence of hypertension.[32–34]
However, it is important to note that the observed effect of age on
the prevalence of hypertension might have partly contributed by
the number of years that the participants have been exposed to
HIV and ART.[35,36]
Given that this study involved both cross-sectional and cohort
studies, we examined whether the different types of study design
used have inﬂuence on the estimated prevalence of hypertension
among EPLWH aged ≥50 years. Interestingly, the estimated
prevalence rates of hypertension obtained from cross-sectional
and cohorts were very similar. This indicates that the selected
EPLWH aged ≥50 years in both cross-sectional and cohort
studies yielded study populations that were similar. It is
important to mention that only 2 studies were conducted in
SSA among studies found to be eligible for inclusion. This may be
due to inadequate research funding and HIV research capacity to
answer relevant research questions in this setting[37] even though
the region accounts for more than two-thirds of people living
with HIV globally.[38]
Findings from this study are consistent with previous studies
that have established a positive relationship between HIV
infection/ART and occurrence of hypertension. Studies have
found that HIV infection can trigger atherogenesis through
persistent activation of immune cell by the virus, even in those
who had achieved viral suppression.[35,39] Also, certain antire-
troviral drugs have been implicated to cause dyslipidemia which
will invariably lead to endothelia damage.[36,40–43] In addition,
prior studies have shown that aging on its own is a risk factor for
hypertension.[32–34] Thus, it was interesting that this study
conﬁrmed that aging contributed to the observed prevalence of
hypertension based on the synergy between aging and HIV
infection. Our observation in this study showed that 2 out 5
EPLWH are hypertensive. It indicates why it is relevant for all
HIV stakeholders to integrate the management of hypertension
and other prevalent co-morbidities into HIV management
package.
Figure 5. Relationship between mean age and hypertension prevalence.
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We ensured that all eligible studies were included in the meta-
analysis as our literature searches were not restricted based on
language, yearofpublication, andgeographic location.Mostof the
studies included were found to be of high quality, indicating low
risk of bias in the prevalence rates of hypertension considered.
However, this studyhas some limitations that isworthmentioning.
Contrary to the observations in high-income countries, it may be
difﬁcult to actually estimate the actual hypertension prevalence in
SSA among EPLWH as people residing in this region have a lower
life expectancy.However, rectifying this limitationwasbeyondour
control as all eligible studies identiﬁed in the literature were
considered. Furthermore, it was impossible to explore heterogene-
ity adequately because individual-patient level characteristics were
not captured in all the included studies.
In conclusion, this study estimated the global prevalence of
hypertension in EPLWH. The present study will serve as a source
of vital information for HIV program implementers and donors
to design a comprehensive management package for HIV
patients.
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